Provided by Tiger Trade Technology Pte. Ltd.

ALPHAMAB-B

8.330
-0.120-1.42%
Volume:841.00K
Turnover:6.93M
Market Cap:8.06B
PE:-59.43
High:8.400
Open:8.305
Low:8.120
Close:8.450
52wk High:15.750
52wk Low:6.230
Shares:968.00M
HK Float Shares:968.00M
Volume Ratio:0.89
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.140
ROE:-9.98%
ROA:-5.47%
PB:4.13
PE(LYR):-59.44
PS:13.33

Loading ...

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on Jskn016, a First-in-Class Trop2/Her3 Bispecific ADC

THOMSON REUTERS
·
Aug 04

Alphamab Oncology Announces Approval from CDE for Jskn033 to Initiate a Phase III Clinical Study

Reuters
·
Aug 04

ALPHAMAB-B wins CDE green light to start Phase III trial of subcutaneous bispecific ADC/PD-L1 combo JSKN033 for hard-to-treat cervical cancer

Bulletin Express
·
Aug 03

Alphamab Oncology - Approval from Cde for Jskn033 to Initiate a Phase Iii Clinical Study for Treatment of Cervical Cancer

THOMSON REUTERS
·
Aug 03

Alphamab Oncology Says China CDE Clears Jskn033 Phase 3 Trial in Recurrent or Metastatic Cervical Cancer

Reuters
·
Aug 03

Alphamab-B Shares Surge 10% on Breakthrough Therapy Designation for Breast Cancer Treatment

Stock News
·
Jul 15

Alphamab Oncology Says China Regulator Grants Breakthrough Tag for Anbenitamab in First-line HER2+ Advanced Breast Cancer

Reuters
·
Jul 14

Alphamab Oncology - Anbenitamab (kn026) Granted Breakthrough Therapy Designation by Nmpa for Her2+ Breast Cancer

THOMSON REUTERS
·
Jul 14

Hang Seng Tech Index Extends Losses to 2%, Knowledge Atlas and Baidu Lead Declines

Deep News
·
Jul 14

ALPHAMAB-B pares 0.02% of outstanding shares in June amid HKD1.11 million buy-back

Bulletin Express
·
Jul 07

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23

Alphamab Oncology AGM: Shareholders Endorse All 2026 Resolutions

Bulletin Express
·
Jun 12

BUZZ-Alphamab climbs most in over 8 weeks on progress of breast cancer treatment

Reuters
·
Jun 11

Alphamab-B Shares Surge on Positive Phase III Trial Results for Breast Cancer Treatment

Stock News
·
Jun 11

Alphamab Says Phase 3 Study of Breast Cancer Drug Meets Primary Endpoint

MT Newswires Live
·
Jun 11

Hong Kong Market Preview: US May CPI Rises 4.2% Year-on-Year; MIIT to Boost R&D for High-End Optoelectronic Chips

Stock News
·
Jun 11

BRIEF-Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint

Reuters
·
Jun 10

Alphamab-B's Phase III Trial for KN026 in First-Line HER2-Positive Advanced Breast Cancer Hits Primary Endpoint

Stock News
·
Jun 10

Alphamab: Anbenitamab Phase III Trial Hits Primary Endpoint in First-Line HER2-Positive Advanced Breast Cancer

Bulletin Express
·
Jun 10

Alphamab Oncology says phase III trial of Anbenitamab plus albumin-bound docetaxel meets primary endpoint in first-line HER2+ advanced breast cancer

Reuters
·
Jun 10